Login to Your Account



Millennium Files For Approval Of Velcade In Multiple Myeloma

By Kim Coghill


Thursday, January 23, 2003
Millennium Pharmaceuticals Inc. filed a new drug application for Velcade, a proteasome inhibitor shown to extend median survival time in relapsed and refractory multiple myeloma patients to 16.4 months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription